De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors

Anna Johansson-Percival, Bo He, Zhi Jie Li, Alva Kjellén, Karen Russell, Ji Li, Irma Larma, Ruth Ganss

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The tumor microenvironment confers profound resistance to anti-cancer immunotherapy. By targeting LIGHT, a member of the TNF superfamily of cytokines, to tumor vessels via a vascular targeting peptide (VTP), we developed a reagent with the dual ability to modulate the angiogenic vasculature and to induce tertiary lymphoid structures (TLSs). LIGHT-VTP triggered the influx of endogenous T cells into autochthonous or syngeneic tumors, which are resistant to immunotherapy. LIGHT-VTP in combination with checkpoint inhibition generated a large number of intratumoral effector and memory T cells with ensuing survival benefits, while the addition of anti-tumor vaccination achieved maximal therapeutic efficacy. Thus, the combination treatments stimulated the trafficking of pre-existing endogenous effector T cells as well as their intratumoral activation and were more successful than current immunotherapies, which fail due to tumor-intrinsic resistance mechanisms.

Original languageEnglish
Pages (from-to)1207-1217
Number of pages11
JournalNature Immunology
Volume18
Issue number11
DOIs
Publication statusPublished - 18 Oct 2017

Fingerprint

Immunotherapy
Blood Vessels
Neoplasms
T-Lymphocytes
Light
Peptides
Tumor Microenvironment
Vaccination
Cytokines
Therapeutics

Cite this

@article{5bd25499e71c40dbab45e9947a9b016d,
title = "De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors",
abstract = "The tumor microenvironment confers profound resistance to anti-cancer immunotherapy. By targeting LIGHT, a member of the TNF superfamily of cytokines, to tumor vessels via a vascular targeting peptide (VTP), we developed a reagent with the dual ability to modulate the angiogenic vasculature and to induce tertiary lymphoid structures (TLSs). LIGHT-VTP triggered the influx of endogenous T cells into autochthonous or syngeneic tumors, which are resistant to immunotherapy. LIGHT-VTP in combination with checkpoint inhibition generated a large number of intratumoral effector and memory T cells with ensuing survival benefits, while the addition of anti-tumor vaccination achieved maximal therapeutic efficacy. Thus, the combination treatments stimulated the trafficking of pre-existing endogenous effector T cells as well as their intratumoral activation and were more successful than current immunotherapies, which fail due to tumor-intrinsic resistance mechanisms.",
author = "Anna Johansson-Percival and Bo He and Li, {Zhi Jie} and Alva Kjell{\'e}n and Karen Russell and Ji Li and Irma Larma and Ruth Ganss",
year = "2017",
month = "10",
day = "18",
doi = "10.1038/ni.3836",
language = "English",
volume = "18",
pages = "1207--1217",
journal = "Nature Immunology",
issn = "1529-2908",
publisher = "Nature Publishing Group",
number = "11",

}

De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors. / Johansson-Percival, Anna; He, Bo; Li, Zhi Jie; Kjellén, Alva; Russell, Karen; Li, Ji; Larma, Irma; Ganss, Ruth.

In: Nature Immunology, Vol. 18, No. 11, 18.10.2017, p. 1207-1217.

Research output: Contribution to journalArticle

TY - JOUR

T1 - De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors

AU - Johansson-Percival, Anna

AU - He, Bo

AU - Li, Zhi Jie

AU - Kjellén, Alva

AU - Russell, Karen

AU - Li, Ji

AU - Larma, Irma

AU - Ganss, Ruth

PY - 2017/10/18

Y1 - 2017/10/18

N2 - The tumor microenvironment confers profound resistance to anti-cancer immunotherapy. By targeting LIGHT, a member of the TNF superfamily of cytokines, to tumor vessels via a vascular targeting peptide (VTP), we developed a reagent with the dual ability to modulate the angiogenic vasculature and to induce tertiary lymphoid structures (TLSs). LIGHT-VTP triggered the influx of endogenous T cells into autochthonous or syngeneic tumors, which are resistant to immunotherapy. LIGHT-VTP in combination with checkpoint inhibition generated a large number of intratumoral effector and memory T cells with ensuing survival benefits, while the addition of anti-tumor vaccination achieved maximal therapeutic efficacy. Thus, the combination treatments stimulated the trafficking of pre-existing endogenous effector T cells as well as their intratumoral activation and were more successful than current immunotherapies, which fail due to tumor-intrinsic resistance mechanisms.

AB - The tumor microenvironment confers profound resistance to anti-cancer immunotherapy. By targeting LIGHT, a member of the TNF superfamily of cytokines, to tumor vessels via a vascular targeting peptide (VTP), we developed a reagent with the dual ability to modulate the angiogenic vasculature and to induce tertiary lymphoid structures (TLSs). LIGHT-VTP triggered the influx of endogenous T cells into autochthonous or syngeneic tumors, which are resistant to immunotherapy. LIGHT-VTP in combination with checkpoint inhibition generated a large number of intratumoral effector and memory T cells with ensuing survival benefits, while the addition of anti-tumor vaccination achieved maximal therapeutic efficacy. Thus, the combination treatments stimulated the trafficking of pre-existing endogenous effector T cells as well as their intratumoral activation and were more successful than current immunotherapies, which fail due to tumor-intrinsic resistance mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=85031770796&partnerID=8YFLogxK

U2 - 10.1038/ni.3836

DO - 10.1038/ni.3836

M3 - Article

VL - 18

SP - 1207

EP - 1217

JO - Nature Immunology

JF - Nature Immunology

SN - 1529-2908

IS - 11

ER -